NCT05646082View on ClinicalTrials.gov

Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Refractory HIV Associated Kaposi Sarcoma
Interventions
DRUG

Dostarlimab in Combination Antiretroviral Therapy

Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.

Trial Locations (1)

SW10 9NH

RECRUITING

Chelsea & Westminster Hospital, London

All Listed Sponsors
lead

Imperial College London

OTHER